In Vitro Luminal Cell Invasion Model via 3D Collagen Culture
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current methods fail to accurately model in vivo invasive processes of luminal cell invasion in breast cancer, particularly for primary human luminal cells, which are essential for understanding and developing targeted therapies, due to the inability to recreate invasive capacity in vitro.
Innovation Solution
An in vitro method involving culturing luminal progenitor cells in a collagen gel with specific growth factors and inhibitors, such as EGF and ROCK inhibitors, to form multicellular organoid units that recapitulate invasive and ductal cell growth, allowing for the screening of anti-migratory drugs.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If luminal progenitor cells are cultured in collagen gel with growth factors to model invasive growth, then the model accuracy and biological relevance are improved, but the culture complexity and difficulty of maintaining viable luminal cells increase
Solution Approach 1:
The patent applies parameter changes by optimizing culture conditions including specific growth factors (EGF, FGF7, FGF10), their concentrations, and combinations. The culture medium parameters are precisely controlled to enable luminal cell invasion in 3D collagen models, transforming previously non-invasive cells into invasive models that accurately reflect in vivo breast cancer progression.
Solution Approach 2:
The patent uses collagen gel as an intermediary extracellular matrix that mediates between the luminal cells and the culture environment. This collagen-based 3D matrix serves as a bridge that enables invasive growth while maintaining cell viability, resolving the contradiction between model accuracy and culture difficulty.
2Reliability
If primary human luminal cells are used to create in vitro invasion models, then the physiological relevance and therapeutic screening value are improved, but the ability to maintain cells in actively dividing state deteriorates
Solution Approach 1:
The patent implements continuous useful action through sustained provision of growth factors (EGF, FGF7, FGF10) in the culture medium. This continuous stimulation maintains luminal cells in an actively dividing, invasive state over extended culture periods, preventing cell senescence and maintaining physiological relevance throughout the experiment duration.
Solution Approach 2:
The patent changes critical culture parameters including growth factor concentrations, collagen gel composition, and oxygen levels to extend the viable culture period of primary luminal cells. These parameter optimizations enable long-term maintenance of cells in an invasive, physiologically relevant state.
3Ease of operation
If traditional 2D culture methods are used for luminal cells, then the ease of operation and established protocols are maintained, but the ability to recapitulate invasive and ductal cell growth deteriorates
Solution Approach 1:
The patent transitions from 2D planar culture to 3D collagen gel culture, adding a spatial dimension that enables luminal cells to exhibit invasive growth patterns and ductal network formation. This dimensional change allows cells to migrate and organize in three-dimensional space, accurately recapitulating in vivo breast cancer invasion while maintaining operational feasibility.
Data Source
AI summary
The present invention relates to an in vitro method of generating cells capable of differentiating to a multicellular organoid unit that morphologically and/or functionally recapitulates invasive and/or ductal cell growth. The present invention further relates to a method of screening for an anti-migratory drug using a multicellular organoid unit obtained in the in vitro method. Additionally, the present invention relates to a culture medium and the respective use of said culture medium in any of said methods according to the present invention.